Literature DB >> 22706472

The lower extremity in Morquio syndrome.

Arjun A Dhawale1, Mihir M Thacker, Mohan V Belthur, Kenneth Rogers, Michael B Bober, William G Mackenzie.   

Abstract

BACKGROUND: The modalities and results of surgical intervention in the lower extremity in children with Morquio syndrome type A [mucopolysaccharidosis-IV (MPS-IVA)] have not been well described. The aims of this study are to define the lower extremity deformities, and describe the results of intervention in MPS-IVA patients.
METHODS: Retrospective chart and radiograph review of 23 MPS-IVA patients with a minimum follow-up of >2 years. Patients were divided into no intervention and surgical groups. Demographic data, surgical details, clinical results, and complications were recorded. Standard lower extremity radiographic measurements made on standing radiographs at initial presentation, preoperatively (in surgical group), and at the final follow-up were used to study the deformities and effects of hip, knee, and ankle surgery. Descriptive statistics were performed.
RESULTS: There were 11 boys and 12 girls. The average age at presentation was 6.8±3.4 years and at the last visit was 13.5±5 years with a mean follow-up of 6.7±3.7 years. Progressive hip subluxation, genu valgum, and ankle valgus were observed in all patients without intervention. Twenty patients had a total of 159 lower extremity surgical procedures (average, 8 procedures per patient). There were 61 hip, 78 knee, and 20 ankle procedures. Surgery resulted in improvement of the center edge angle, femoral head coverage, lateral distal femoral angle, medial proximal tibial angle, tibiofemoral angle, and lateral distal tibial angle. Mechanical axis of the lower extremities improved after intervention. Six patients (12 hips) had recurrence of hip subluxation after acetabular osteotomies and/or femoral varus derotation osteotomy, and 8 patients (16 knees) had postoperative genu valgum recurrence requiring subsequent intervention. There was no recurrent hip subluxation after shelf acetabuloplasty.
CONCLUSIONS: Progressive hip subluxation, genu valgum, and ankle valgus were seen and often needed surgery. After shelf acetabuloplasty and varus derotation osteotomy, there was no recurrent hip subluxation. Recurrence after genu valgum correction was common. LEVEL OF EVIDENCE: Level IV, therapeutic case series.

Entities:  

Mesh:

Year:  2012        PMID: 22706472     DOI: 10.1097/BPO.0b013e318259fe57

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  19 in total

Review 1.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

2.  Guided growth may not be the best option for knee valgus deformity in adolescent patients with Morquio-A.

Authors:  D Colmenares-Bonilla; M Vasconcelos-Martinez; J Guerra-Jasso; L Ocampo-Perez
Journal:  Musculoskelet Surg       Date:  2016-12-07

3.  Activity of daily living for Morquio A syndrome.

Authors:  Eriko Yasuda; Yasuyuki Suzuki; Tsutomu Shimada; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Li Xie; Freeman Miller; Tariq Rahman; Heidi H Kecskemethy; Kyoko Nagao; Thierry Morlet; Thomas H Shaffer; Yasutsugu Chinen; Hiromasa Yabe; Akemi Tanaka; Haruo Shintaku; Kenji E Orii; Koji O Orii; Robert W Mason; Adriana M Montaño; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-04-25       Impact factor: 4.797

Review 4.  Morquio A syndrome: diagnosis and current and future therapies.

Authors:  Shunji Tomatsu; Eriko Yasuda; Pravin Patel; Kristen Ruhnke; Tsutomu Shimada; William G Mackenzie; Robert Mason; Mihir M Thacker; Mary Theroux; Adriana M Montaño; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; William S Sly; Daniel Rowan; Yasuyuki Suzuki; Tado Orii
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 5.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

Review 6.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.

Authors:  C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu
Journal:  Mol Genet Metab       Date:  2013-04-10       Impact factor: 4.797

7.  Current and emerging treatments and surgical interventions for Morquio A syndrome: a review.

Authors:  Shunji Tomatsu; William G Mackenzie; Mary C Theroux; Robert W Mason; Mihir M Thacker; Thomas H Shaffer; Adriana M Montaño; Daniel Rowan; William Sly; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; Eriko Yasuda; Kristen Ruhnke; Yasuyuki Suzuki; Tadao Orii
Journal:  Res Rep Endocr Disord       Date:  2012-12

8.  Current therapies for Morquio A syndrome and their clinical outcomes.

Authors:  Kazuki Sawamoto; Yasuyuki Suzuki; William G Mackenzie; Mary C Theroux; Christian Pizarro; Hiromasa Yabe; Kenji E Orii; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2016-07-28       Impact factor: 0.694

9.  Current and emerging management options for patients with Morquio A syndrome.

Authors:  Mohamed F Algahim; G Hossein Almassi
Journal:  Ther Clin Risk Manag       Date:  2013-02-11       Impact factor: 2.423

Review 10.  International guidelines for the management and treatment of Morquio A syndrome.

Authors:  Christian J Hendriksz; Kenneth I Berger; Roberto Giugliani; Paul Harmatz; Christoph Kampmann; William G Mackenzie; Julian Raiman; Martha Solano Villarreal; Ravi Savarirayan
Journal:  Am J Med Genet A       Date:  2014-10-24       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.